IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Fresenius Kabi Buys Indian Generics and API Firm

11:11 AM MDT | April 28, 2008 | Deepti Ramesh

Fresenius Kabi (Bad Homburg, Germany), a unit of health care group Fresenius SE, says it has acquired 73.3% stake in Dabur Pharma (New Delhi) for about €139 million ($224 million). Fresenius Kabi says it has also offered to acquire a further 20% stake in Dabur Pharma for Rupees 76.50/share. The two companies have signed a share purchase agreement, and the transaction awaits regulatory approval, Fresenius Kabi says. Burman: India pharma market is attractive. Dabur Pharma is a leading global supplier of generic drugs and active pharmaceutical ingredients...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa